SPECIAL REPORT
Real-world efficacy and safety
Switching anti-CD20 therapies
Patient-reported outcomes (PROs)
Effect on cortical lesions Read More
Latest News
ACTRIMS Forum 2025 Highlights – Saturday, March 1, 2025
March 1, 2025The following summarizes some of the highlights from Day 2 if the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2025.
ACTRIMS Forum 2025 Highlights – Friday, February 28, 2025
February 28, 2025The following summarizes some of the highlights from Day 1 of the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2025.
CLINICAL CASES IN MS: A 38-YEAR-OLD WOMAN PLANNING PREGNANCY
February 27, 2025Click here to watch Dr. Kristen Krysko discuss the case and the responses to the survey.
RJ, age 38 years, has a 15-year history of relapsing-remitting multiple sclerosis. She initially presented with highly-active MS and was started on beta-interferon-1a 44µg. She continued to have significant clinical disease activity and ongoing MRI lesions in both brain and spine. She was transitioned to fingolimod in 2012. Read More